Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Bilateral interstitial pneumonia after recent trip to Peru
Journal Information
Vol. 37. Issue 9.
Pages 609-610 (November 2019)
Visits
4042
Vol. 37. Issue 9.
Pages 609-610 (November 2019)
Diagnosis at first sight
Full text access
Bilateral interstitial pneumonia after recent trip to Peru
Neumonía intersticial bilateral tras viaje reciente a Perú
Visits
4042
Eñaut Agirrea,d,
Corresponding author
, Antía Osoriob, Juan Manuel Casas Fernández de Tejerinac, Francisco Rodríguez-Arrondod, Yolanda Salicio Bermejoe
a Medicina Interna, Hospital Universitario Donostia, Donostia-San Sebastián, Guipúzcoa, Spain
b Anestesiología y Reanimación, Hospital Universitario Donostia, Donostia-San Sebastián, Guipúzcoa, Spain
c Medicina Interna, Complejo Hospitalario de Navarra, Iruña-Pamplona, Navarra, Spain
d Unidad de Enfermedades Infecciosas, Hospital Universitario Donostia, Donostia-San Sebastián, Guipúzcoa, Spain
e Servicio de Microbiología, Hospital Universitario Donostia, Donostia-San Sebastián, Guipúzcoa, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Full Text
Case report

We present two cases of lung involvement after travel to Peru.

Case 1: a 29-year-old female with a history of hypothyroidism and allergic rhinitis. The patient and her companion (case 2), both of Spanish nationality and residence, presented as a determinant a recent three-week stay in Peru, starting in the southern region and then in the Amazon area. She reported having stayed overnight in huts with adequate sanitary conditions, contact with amphibian and ophidian species and bathing in fresh water. She had no direct contact with birds. She had not taken traveller's advice or undergone any prophylaxis. Valid childhood vaccinations.

She consulted with a 40°C fever, which started 10 days after her return, associated with a productive cough and exertional dyspnoea. She was assessed initially at another centre, with antigenuria (Streptococcus pneumoniae, Legionella) and negative blood cultures, and chest X-ray with bibasilar interstitial pattern. Treatment was started with amoxicillin and azithromycin. After one week, she consulted at our centre for a persisting fever and was admitted to complete testing.

At admission, the presence of bibasilar crackles was of note. The rest of the examination was normal. The blood tests revealed: PCT 0.1 and CRP 80. Normal general blood chemistry. ABG: hypoxaemia without hypercapnia. Hb: 14.1; platelets 274,000; 8420 white blood cells (67.5% N; 22% lymphocytes; 8.9% monocytes; 0.8% eosinophils). The chest X-ray (Fig. 1) revealed poorly defined bilateral nodular infiltrates. Plasmodium antigen testing and the thick drop test were performed, with a negative result.

Fig. 1.

Chest X-ray upon admission of case 1.

(0.05MB).

Treatment was started with ceftriaxone and levofloxacin, and extended microbiological testing, CT scan and fibrobronchoscopy were requested.

The CT scan (Fig. 2) showed multiple bilateral lung nodules; mediastinal and pathological bilateral hilar lymphadenopathies; hepatic hilar lymphadenopathies of a limited size, as well as small retroperitoneal, pelvic and inguinal lymphadenopathies. The sputum culture was negative for common bacteria, mycobacteria and fungi. The pharyngeal smear and QuantiFERON-TB Gold test were negative. Serological testing for hepatitis B and C, HIV, CMV, Epstein–Barr virus, varicella-zoster, IgM, Zika, chikungunya, dengue, hantavirus, Coxiella burnetii, Mycoplasma pneumoniae and Leptospira were negative. The video bronchoscopy did not reveal macroscopic findings. Bronchial aspirate and bronchoalveolar lavage were collected, with the Gram stain, KOH test, specific cultures for common bacteria, mycobacteria, Nocardia and fungi and molecular techniques for Pneumocystis and CMV being negative. Serology was ordered for endemic mycoses.

Fig. 2.

Chest CT scan section performed in case 1 which shows bilateral nodular infiltrates.

(0.07MB).

When the fever disappeared and the dyspnoea improved, she was discharged on treatment with levofloxacin.

Clinical course

After a few days, the serology determined a positive result for Paracoccidioides brasiliensis (P. brasiliensis) and a negative result for Histoplasma, Blastomyces and Coccidioides. Treatment was started with itraconazole 100mg/24h, following the Brazilian guidelines.1 The subsequent clinical course was favourable, completing six months of treatment with no incidents. The patient remained asymptomatic, with normalisation of the acute phase reactants and disappearance of the lung lesions.

Case 2: male, 31-years-old. No relevant history. He was admitted at another centre due to fever, myalgia and asthenia in the same time frame as the patient in case 1. An X-ray was performed with a diffuse bilateral reticulonodular interstitial pattern (Fig. 3). Testing was completed with a video bronchoscopy (BAS and BAL), CT scan and microbiological testing similar to that of case 1, with no aetiological result. Serology was ordered for endemic mycoses. This was initially negative, but turned positive for P. brasiliensis after 10 days. He received treatment with itraconazole, with a satisfactory clinical course.

Fig. 3.

Chest X-ray upon admission of case 2.

(0.04MB).
Comments

Paracoccidioidomycosis is a fungal infection caused by the fungus P. brasiliensis which is considered endemic to the American continent, with cases reported from Mexico to Argentina. Brazil is the country with the greatest endemicity.2,3

The infection is caused by inhalation of spores when exposed to the rural environment. The majority (96–98%) of those infected never develop the disease. Among symptomatic individuals, the most common form (90%) is the chronic one, with periods of latency of years/decades, with predominance of lung and mucous membrane involvement. The acute/sub-acute form happens after incubation for 30–60 days,4 occurs predominantly in individuals under the age of 30 and the involvement of the reticuloendothelial system (hepatosplenomegaly and lymphadenopathies) and of the skin.5

The diagnostic techniques with the best performance are direct vision in samples prepared with KOH and serology by means of double immunodiffusion.6

On a state level, there are 34 cases reported to date, 21 of which are published. All of them are of chronic presentation in long-term travellers or immigrants.7,8

Our case presents various particularities: (a) it is the first case in short-term travellers of which we are aware at state level; (b) to date acute forms had not been reported in Spain; (c) significant lung involvement despite being an acute form, in which this involvement is rare (10%), and (d) absence of direct diagnosis by means of cultures or direct vision.

Finally, we would like to highlight that, although it is rare, there is a maintained incidence of paracoccidioidomycosis and other endemic mycoses, both in travellers and in immigrants,9 which makes it necessary to maintain a high level of suspicion in patients with a history of compatible geographic exposure.10

Conflicts of interest

The authors declare that they have no conflicts of interest.

References
[1]
M.A. Shikanai-Yasuda, R.P. Mendes, A.L. Colombo, F. de Queiroz-Telles, A.S. Gonçalves Kono, A.M.M. Paniago, et al.
Brazilian guidelines for the clinical management of paracoccidioidomycosis.
Rev Soc Bras Med Trop, 50 (2017), pp. 715-740
[2]
F. Bellissimo-Rodrigues, A.A. Machado, R. Martinez.
Paracoccidioidomycosis epidemiological features of a 1,000-cases series from a hyperendemic area on the southeast of Brazil.
Am J Trop Med Hyg, 85 (2011), pp. 546-550
[3]
P.M. Peçanha, M.E.B. Ferreira, M.A.M. Peçanha, E.B. Schmidt, M.L. de Araújo, R.L. Zanotti, et al.
Paracoccidioidomycosis: epidemiological and clinical aspects in 546 cases studied in the state of Espírito Santo, Brazil.
Am J Trop Med Hyg, 97 (2017), pp. 836-844
[4]
R. Buccheri, Z. Khoury, L.C.B. Barata, G. Benard.
Incubation period and early natural history events of the acute form of paracoccidioidomycosis: lessons from patients with a single Paracoccidioides spp. exposure.
Mycopathologia, 181 (2016), pp. 435-439
[5]
P.M. De Macedo, R. Almeida-Paes, D.F.S. Freitas, A.G. Varon, A.G. Paixão, A.R. Romão, et al.
Acute juvenile Paracoccidioidomycosis: a 9-year cohort study in the endemic area of Rio de Janeiro, Brazil.
PLoS Negl Trop Dis, 11 (2017), pp. 1-11
[6]
Restrepo A, Tobón AM, Cano LE. Editors: Bennett J; Dolin R; Blaser MJ. Mand Douglas, Bennett's Princ Pract Infect Dis (Eighth Ed) ISBN 9781455748013. 2015;2(269-Paracoccidioidomycosis):2995–3002. Elsevier. https://doi.org/10.1016/B978-1-4557-4801-3.00269-1.
[7]
D. Molina-Morant, A. Sánchez-Montalvá, F. Salvador, A. Sao-Avilés, I. Molina.
Imported endemic mycoses in Spain: evolution of hospitalized cases, clinical characteristics and correlation with migratory movements, 1997–2014.
PLoS Negl Trop Dis, 12 (2018), pp. 1-11
[8]
M.J. Buitrago, M. Cuenca-Estrella.
Epidemiología actual y diagnóstico de laboratorio de las micosis endémicas en España.
Enferm Infecc Microbiol Clin, 30 (2012), pp. 407-413
[9]
H.J.F. Salzer, R.J. Stoney, K.M. Angelo, T. Rolling, M.P. Grobusch, M. Libman, et al.
Epidemiological aspects of travel-related systemic endemic mycoses: a GeoSentinel analysis, 1997–2017.
J Travel Med, 25 (2018), pp. 1-6
[10]
R. Martinez.
New trends in paracoccidioidomycosis epidemiology.
J Fungi, 3 (2017), pp. 1

Please cite this article as: Agirre E, Osorio A, Casas Fernández de Tejerina JM, Rodríguez-Arrondo F, Salicio Bermejo Y. Neumonía intersticial bilateral tras viaje reciente a Perú. Enferm Infecc Microbiol Clin. 2019;37:609–610.

Copyright © 2019. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.eimce.2021.08.010
No mostrar más